Emerging EPO and EPO receptor regulators and signal transducers

Blood

Volumn 125, Issue 23, 2015, Pages 3536-3541

  Kuhrt, David ^a   Wojchowski, Don M ^a,b  

^a Maine Medical Center Research Institute   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; RAF PROTEIN; RAS PROTEIN; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; EPO PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; STAT5 PROTEIN;

ADIPOGENESIS; BIOGENESIS; CELL PROTECTION; CELL SURVIVAL; HUMAN; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RETINA CELL; REVIEW; SIGNAL TRANSDUCTION; ANEMIA; ANIMAL; BIOSYNTHESIS; CYTOLOGY; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; RAT;

ANEMIA; ANIMALS; ERYTHROID PRECURSOR CELLS; ERYTHROPOIESIS; ERYTHROPOIETIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; JANUS KINASE 2; MAP KINASE SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASES; RAS PROTEINS; RATS; RECEPTORS, ERYTHROPOIETIN; STAT5 TRANSCRIPTION FACTOR;

EID: 84930966112     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-11-575357     Document Type: Review

References (93)

1. Reissmann KR. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blood. 1950;5(4):372-380.
2. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977;252(15):5558-5564.
3. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313(6005):806-810.
4. Rizzo JD, Brouwers M, Hurley P, et al American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045-4059.
5. D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell. 1989;57(2):277-285.
6. Constantinescu SN, Wu H, Liu X, Beyer W, Fallon A, Lodish HF. The anemic Friend virus gp55 envelope protein induces erythroid differentiation in fetal liver colony-forming units-erythroid. Blood. 1998;91(4):1163-1172.
7. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993;74(2):227-236.
8. Livnah O, Johnson DL, Stura EA, et al. An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol. 1998;5(11):993-1004.
9. Sokol L, Luhovy M, Guan Y, Prchal JF, Semenza GL, Prchal JT. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood. 1995;86(1):15-22.
10. Bartnicki P, Kowalczyk M, Rysz J. The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection. Med Sci Monit. 2013;19:599-605.
11. Debeljak N, Solár P, Sytkowski AJ. Erythropoietin and cancer: the unintended consequences of anemia correction. Front Immunol. 2014;5:563.
12. Mastromarino V, Musumeci MB, Conti E, Tocci G, Volpe M. Erythropoietin in cardiac disease: effective or harmful? J Cardiovasc Med (Hagerstown). 2013;14(12):870-878.
13. Nguyen AQ, Cherry BH, Scott GF, Ryou MG, Mallet RT. Erythropoietin: powerful protection of ischemic and post-ischemic brain. Exp Biol Med (Maywood). 2014;239(11):1461-1475.
14. Sanchis-Gomar F, Garcia-Gimenez JL, Pareja-Galeano H, Romagnoli M, Perez-Quilis C, Lippi G. Erythropoietin and the heart: physiological effects and the therapeutic perspective. Int J Cardiol. 2014;171(2):116-125.
15. Wang L, Di L, Noguchi CT. Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system. Int J Biol Sci. 2014;10(8):921-939.
16. Zhang Y, Wang L, Dey S, et al. Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci. 2014;15(6):10296-10333.
17. Elliott S, Sinclair A, Collins H, Rice L, Jelkmann W. Progress in detecting cell-surface protein receptors: the erythropoietin receptor example. Ann Hematol. 2014;93(2):181-192.
18. Carraway MS, Suliman HB, Jones WS, Chen CW, Babiker A, Piantadosi CA. Erythropoietin activates mitochondrial biogenesis and couples red cell mass to mitochondrial mass in the heart. Circ Res. 2010;106(11):1722-1730.
19. Mowat FM, Gonzalez F, Luhmann UF, et al. Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy. Am J Pathol. 2012;180(4):1726-1739.
20. Kumar SM, Zhang G, Bastian BC, et al. Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene. 2012;31(13):1649-1660.
21. Teng R, Gavrilova O, Suzuki N, et al. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nat Commun. 2011;2:520.
22. Suzuki N, Hirano I, Pan X, Minegishi N, Yamamoto M. Erythropoietin production in neuroepithelial and neural crest cells during primitive erythropoiesis. Nat Commun. 2013;4:2902.
23. Yamaguchi Y, Hayashi A, Campagnoni CW, Kimura A, Inuzuka T, Baba H. L-MPZ, a novel isoform of myelin P0, is produced by stop codon readthrough. J Biol Chem. 2012;287(21):17765-17776.
24. Asada N, Takase M, Nakamura J, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest. 2011;121(10):3981-3990.
25. Pan X, Suzuki N, Hirano I, Yamazaki S, Minegishi N, Yamamoto M. Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice. PLoS ONE. 2011;6(10):e25839.
26. Suzuki N, Obara N, Pan X, et al. Specific contribution of the erythropoietin gene 39 enhancer to hepatic erythropoiesis after late embryonic stages. Mol Cell Biol. 2011;31(18):3896-3905.
27. Rankin EB, Wu C, Khatri R, et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012;149(1):63-74.
28. Bunn HF. Erythropoietin. Cold Spring Harb Perspect Med. 2013;3(3):a011619.
29. Scortegagna M, Ding K, Zhang Q, et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood. 2005;105(8):3133-3140.
30. Haase VH. Regulation of erythropoiesis by hypoxiainducible factors. Blood Rev. 2013;27(1):41-53.
31. Anderson SA, Nizzi CP, Chang YI, et al. The IRP1-HIF-2α axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption. Cell Metab. 2013;17(2):282-290.
32. Chen R, Xu M, Hogg RT, et al. The acetylase/deacetylase couple CREB-binding protein/Sirtuin 1 controls hypoxia-inducible factor 2 signaling. J Biol Chem. 2012;287(36):30800-30811.
33. Xu M, Nagati JS, Xie J, et al. An acetate switch regulates stress erythropoiesis. Nat Med. 2014;20(9):1018-1026.
34. Krishnan M, Nissenson AR. New alternatives in anemia treatment: biosimilars and HIF stabilizers. Nephrol News Issues. 2014;28(6):24-28.
35. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood. 1991;77(12):2583-2590.
36. Zon LI, Youssoufian H, Mather C, Lodish HF, Orkin SH. Activation of the erythropoietin receptor promoter by transcription factor GATA-1. Proc Natl Acad Sci USA. 1991;88(23):10638-10641.
37. Feng D, Kan YW. The binding of the ubiquitous transcription factor Sp1 at the locus control region represses the expression of beta-like globin genes. Proc Natl Acad Sci USA. 2005;102(28):9896-9900.
38. Lacombe J, Krosl G, Tremblay M, et al. Genetic interaction between Kit and Scl. Blood. 2013;122(7):1150-1161.
39. Becker V, Schilling M, Bachmann J, et al. Covering a broad dynamic range: information processing at the erythropoietin receptor. Science. 2010;328(5984):1404-1408.
40. Singh S, Verma R, Pradeep A, et al. Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles. PLoS ONE. 2012;7(1):e29064.
41. Sulahian R, Cleaver O, Huang LJ. Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia. Blood. 2009;113(21):5287-5297.
42. Bulut GB, Sulahian R, Yao H, Huang LJ. Cbl ubiquitination of p85 is essential for Epo-induced EpoR endocytosis. Blood. 2013;122(24):3964-3972.
43. Meyer L, Deau B, Forejtníková H, et al. beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood. 2007;109(12):5215-5222.
44. Forejtnikovà H, Vieillevoye M, Zermati Y, et al. Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood. 2010;116(24):5357-5367.
45. Nai A, Lidonnici MR, Rausa M, et al. The second transferrin receptor regulates red blood cell production in mice. Blood. 2015;125(7):1170-1179.
46. Chen J, Chloupková M. Abnormal iron uptake and liver cancer. Cancer Biol Ther. 2009;8(18):1699-1708.
47. Verma R, Su S, McCrann DJ, et al. RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast development. J Exp Med. 2014;211(9):1715-1722.
48. Coulon S, Dussiot M, Grapton D, et al. Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia. Nat Med. 2011;17(11):1456-1465.
49. Wu J, Ji C, Xie F, et al. FcalphaRI (CD89) alleles determine the proinflammatory potential of serum IgA. J Immunol. 2007;178(6):3973-3982.
50. Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in b-thalassemia. Nat Med. 2014;20(4):398-407.
51. Arcasoy MO, Jiang X. Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor. Br J Haematol. 2005;130(1):121-129.
52. Khalaf WF, White H, Wenning MJ, Orazi A, Kapur R, Ingram DA. K-Ras is essential for normal fetal liver erythropoiesis. Blood. 2005;105(9):3538-3541.
53. Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood. 2006;108(6):2041-2044.
54. Zhang J, Liu Y, Beard C, et al. Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. Blood. 2007;109(12):5238-5241.
55. Larghero J, Gervais N, Cassinat B, et al. Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells. Blood. 2005;105(9):3743-3745.
56. Blanc L, Ciciotte SL, Gwynn B, et al. Critical function for the Ras-GTPase activating protein RASA3 in vertebrate erythropoiesis and megakaryopoiesis. Proc Natl Acad Sci USA. 2012;109(30):12099-12104.
57. Chang T, Krisman K, Theobald EH, et al. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013;123(1):335-339.
58. Rubiolo C, Piazzolla D, Meissl K, et al. A balance between Raf-1 and Fas expression sets the pace of erythroid differentiation. Blood. 2006;108(1):152-159.
59. Wannatung T, Lithanatudom P, Leecharoenkiat A, Svasti S, Fucharoen S, Smith DR. Increased erythropoiesis of beta-thalassaemia/Hb E proerythroblasts is mediated by high basal levels of ERK1/2 activation. Br J Haematol. 2009;146(5):557-568.
60. Bélanger LF, Roy S, Tremblay M, et al. Mek2 is dispensable for mouse growth and development. Mol Cell Biol. 2003;23(14):4778-4787.
61. Menon MP, Fang J, Wojchowski DM. Core erythropoietin receptor signals for late erythroblast development. Blood. 2006;107(7):2662-2672.
62. Guihard S, Clay D, Cocault L, et al. The MAPK ERK1 is a negative regulator of the adult steady-state splenic erythropoiesis. Blood. 2010;115(18):3686-3694.
63. Kumkhaek C, Aerbajinai W, Liu W, et al. MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34+ cells through the Raf/MEK/ERK pathway. Blood. 2013;121(16):3216-3227.
64. Kalfa TA, Zheng Y. Rho GTPases in erythroid maturation. Curr Opin Hematol. 2014;21(3):165-171.
65. Arai A, Kanda E, Miura O. Rac is activated by erythropoietin or interleukin-3 and is involved in activation of the Erk signaling pathway. Oncogene. 2002;21(17):2641-2651.
66. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828-851.
67. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990;248(4953):378-381.
68. Koulnis M, Porpiglia E, Porpiglia PA, et al. Contrasting dynamic responses in vivo of the Bcl-xL and Bim erythropoietic survival pathways. Blood. 2012;119(5):1228-1239.
69. Abutin RM, Chen J, Lung TK, Lloyd JA, Sawyer ST, Harada H. Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells. Exp Hematol. 2009;37(2):151-158.
70. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 1999;98(2):181-191.
71. Dev A, Byrne SM, Verma R, Ashton-Rickardt PG, Wojchowski DM. Erythropoietin-directed erythropoiesis depends on serpin inhibition of erythroblast lysosomal cathepsins. J Exp Med. 2013;210(2):225-232.
72. Rhodes MM, Kopsombut P, Bondurant MC, Price JO, Koury MJ. Bcl-x(L) prevents apoptosis of latestage erythroblasts but does not mediate the antiapoptotic effect of erythropoietin. Blood. 2005;106(5):1857-1863.
73. Repnik U, Hafner Cesen M, Turk B. Lysosomal membrane permeabilization in cell death: concepts and challenges. Mitochondrion. 2014;19(pt A):49-57.
74. De Franceschi L, Bertoldi M, Matte A, et al. Oxidative stress and b-thalassemic erythroid cells behind the molecular defect. Oxid Med Cell Longev. 2013;2013:985210.
75. Sangokoya C, Telen MJ, hi JT. microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood. 2010;116(20):4338-4348.
76. Koulnis M, Liu Y, Hallstrom K, Socolovsky M. Negative autoregulation by Fas stabilizes adult erythropoiesis and accelerates its stress response. PLoS ONE. 2011;6(7):e21192.
77. Carlile GW, Smith DH, Wiedmann M. A nonapoptotic role for Fas/FasL in erythropoiesis. FEBS Lett. 2009;583(4):848-854.
78. An X, Schulz VP, Li J, et al. Global transcriptome analyses of human and murine terminal erythroid differentiation. Blood. 2014;123(22):3466-3477.
79. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-1790.
80. Jedidi A, Marty C, Oligo C, et al. Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood. 2009;114(9):1842-1851.
81. Marty C, Saint-Martin C, Pecquet C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood. 2014;123(9):1372-1383.
82. Russell RC, Sufan RI, Zhou B, et al. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med. 2011;17(7):845-853.
83. Karur VG, Lowell CA, Besmer P, Agosti V, Wojchowski DM. Lyn kinase promotes erythroblast expansion and late-stage development. Blood. 2006;108(5):1524-1532.
84. Shintani T, Ohara-Waki F, Kitanaka A, Tanaka T, Kubota Y. Cbl negatively regulates erythropoietin-induced growth and survival signaling through the proteasomal degradation of Src kinase. Blood Cells Mol Dis. 2014;53(4):211-218.
85. Schnöder TM, Arreba-Tutusaus P, Griehl I, et al. Epo-induced erythroid maturation is dependent on Plcg1 signaling [published online ahead of print November 14, 1014]. Cell Death Differ.
86. Girotti MR, Lopes F, Preece N, et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell. 2015;27(1):85-96.
87. de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122(2):227-238.
88. Menon MP, Karur V, Bogacheva O, Bogachev O, Cuetara B, Wojchowski DM. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J Clin Invest. 2006;116(3):683-694.
89. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-684.
90. Rochette L, Gudjoncik A, Guenancia C, Zeller M, Cottin Y, Vergely C. The iron-regulatory hormone hepcidin: a possible therapeutic target? Pharmacol Ther. 2015;146:35-52.
91. Grover A, Mancini E, Moore S, et al. Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate. J Exp Med. 2014;211(2):181-188.
92. Zhao W, Kitidis C, Fleming MD, Lodish HF, Ghaffari S. Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood. 2006;107(3):907-915.
93. Hellström-Lindberg E, van de Loosdrecht A. Erythropoiesis stimulating agents and other growth factors in low-risk MDS. Best Pract Res Clin Haematol. 2013;26(4):401-410.